Skip to main
XTNT

XTNT Stock Forecast & Price Target

XTNT Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Xtant Medical Holdings is a medical technology company with a focus on developing and commercializing spinal implant systems and orthobiologics. The company has a strong portfolio of products used by orthopedic surgeons to treat various spinal disorders, and has recently increased its revenue guidance for FY26 thanks to a new agreement with Dilon Technologies. Despite past struggles with achieving scale and attention from investors, XTNT's current efforts to grow into a $150M-$200M global orthobiologics company present a favorable risk/reward opportunity. With a strong capital position and increasing interest from distributors, we anticipate faster-than-expected top-line growth, particularly in the orthobiologics segment, leading to potential share price appreciation.

Bears say

Xtant Medical Holdings is a medical technology company focused on orthobiologic and spinal implant systems for spinal fusion procedures. The company has recently launched a new addition to its bone graft portfolio and raised its revenue guidance for FY26, which could lead to increased revenue and improved gross margins. However, the company still faces risks from competition, legacy performance, and the need for additional capital. The company trades at a discount to its peers and is expected to continue growing through the launch of new products and increasing distributor interest.

XTNT has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Xtant Medical Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Xtant Medical Holdings (XTNT) Forecast

Analysts have given XTNT a Strong Buy based on their latest research and market trends.

According to 1 analysts, XTNT has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Xtant Medical Holdings (XTNT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.